
|Videos|December 17, 2020
IMbrave150 for HCC
Author(s)Targeted Oncology
Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
2
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5

































